

Pain Medication Tapering for Patients With Persistent Spinal Pain Syndrome Type 2, Treated With Spinal Cord Stimulation.

NCT05861609

Status	RECRUITING
Phase	Not Applicable
Sponsor	Moens Maarten
Enrollment	195 participants

Key Eligibility Criteria

Inclusion (5)

- Patients with PSPS T2, defined as patients suffering from neuropathic pain of radicular origin with pain in the lower back and/or leg(s), of an intensity of at least 4/10 on the Numeric Rating Scale, for a period of at least 6 months after a minimum of one anatomically successful spinal surgery and being refractory to conservative treatment (according to Belgian reimbursement rules from January 1st, 2018)
- Patients need to be scheduled for SCS to be eligible for participation in the study
- Currently taking opioids
- years and older
- Speaking and reading Dutch or French

Exclusion (6)

- Being actively treated for cancer.
 - Having a life expectancy below 6 months.
 - Receiving intrathecal drug delivery.
 - Patients with contraindications for Clonidine (e.g., known hypotension which requires medication) or for Buprenorphine/Naloxone (e.g., severe respiratory insufficiency, hepatic insufficiency).
 - Epilepsy treated by Pregabalin.
- ... and 1 more (see full listing online)

Locations (3 total)

Universitair Ziekenhuis Brussel, Jette, Belgium
Heilig Hart Ziekenhuis Lier, Lier, Belgium
AZ Delta, Roeselare, Belgium

<https://clinicaltrials.gov/study/NCT05861609>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).